Skip to main content

Norgestimate and Ethinyl Estradiol Medicare Part D Coverage

Brand name: Tri-Lo-Sprintec
Dosage form
KIT
91%
of Medicare Part D plans
cover Norgestimate and Ethinyl Estradiol
5,007 of 5,530 plans
2.3
Avg. formulary tier
$15.00
Median 30-day copay
$0.00–$30.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify Norgestimate and Ethinyl Estradiol. Lower tiers = lower copays.

Tier 1 - Preferred Generic 3%
165 plans • avg $0.00/mo
Tier 2 - Generic 70%
3,483 plans • avg $1.45/mo
Tier 3 - Preferred Brand 24%
1,195 plans • avg $0.94/mo
Tier 4 - Non-Preferred Drug 3%
164 plans • avg $2.30/mo

Find the cheapest plan for Norgestimate and Ethinyl Estradiol

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for Norgestimate and Ethinyl Estradiol →

Get Norgestimate and Ethinyl Estradiol Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

Norgestimate and Ethinyl Estradiol Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about Norgestimate and Ethinyl Estradiol

91% of Medicare Part D plans cover Norgestimate and Ethinyl Estradiol. It is most commonly placed on Tier 2. Coverage varies by plan and geographic area.

The median 30-day copay for Norgestimate and Ethinyl Estradiol on Medicare Part D is $15.00 at a preferred pharmacy. Costs range from $0.00 to $30.00 depending on the plan.

Norgestimate and Ethinyl Estradiol is placed on Tier 2 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for Norgestimate and Ethinyl Estradiol. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →